<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112655</url>
  </required_header>
  <id_info>
    <org_study_id>DiTECT-HAT-WP4</org_study_id>
    <nct_id>NCT03112655</nct_id>
  </id_info>
  <brief_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure</brief_title>
  <acronym>DiTECT-WP4</acronym>
  <official_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study validates the diagnostic performance of cerebrospinal fluid neopterin&#xD;
      quantification and of blood and cerebrospinal fluid trypanosomal spliced leader RNA detection&#xD;
      for assessing outcome after treatment of human African trypanosomiasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, the prevalence of Trypanosoma brucei gambiense human African&#xD;
      trypanosomiasis (HAT) has fallen and HAT has been targeted for elimination. Development of&#xD;
      safe and efficacious drugs for HAT, applicable in an elimination context, is considered as a&#xD;
      high priority. The drug developmental process is however slowed down by the need to follow-up&#xD;
      treated patients for 18 months to decide on cure. For timely diagnosis of treatment failure&#xD;
      in clinical trials, patients should have control visits with follow-up examinations at 6, 12&#xD;
      and 18 months after treatment. Furthermore, due to repeated lumbar punctures, treated&#xD;
      patients refrain to present for control visits spontaneously, and tend not to comply with&#xD;
      follow-up. Clinical trials on new drugs for HAT would therefore be accelerated by&#xD;
      availability of an early test of cure. Trypanosomal spliced leader (SL)-RNA, neopterin &amp;&#xD;
      5-hydroxytryptophan are good candidates for accurate and shortened treatment follow-up. In&#xD;
      particular SL-RNA detection in blood offers an opportunity for non-invasive post-treatment&#xD;
      follow-up.&#xD;
&#xD;
      The objective of the DiTECT-HAT-WP4 study is to validate the diagnostic performance of&#xD;
      cerebrospinal fluid neopterin &amp; 5-hydroxytryptophan quantification and of blood and&#xD;
      cerebrospinal fluid trypanosomal spliced leader RNA detection for assessing treatment&#xD;
      outcome. The DiTECT-HAT-WP4 study is embedded into an ongoing therapeutic phase II/III study&#xD;
      (DNDi-OXA-02-HAT) testing a new oral single dose drug against HAT. Within the Framework of&#xD;
      the therapeutical trial, patients will have post-treatment examinations, including blood and&#xD;
      cerebrospinal fluid examination at day 11, and during follow-up at month 6, month 12 and&#xD;
      month 18. Combination of DiTECT-HAT-WP4 with this ongoing clinical trial allows evaluation of&#xD;
      new treatment outcome assessment markers during follow-up without the need for additional&#xD;
      lumbar or venipunctures. The volumes of venous blood and cerebrospinal fluid taken will be&#xD;
      increased by 2.5 mls for the DiTECT-HAT-WP4 study.&#xD;
&#xD;
      Reverse transcriptase real time PCR for spliced leader RNA detection in blood and&#xD;
      cerebrospinal fluid and neopterin detection will be carried out in the reference laboratory&#xD;
      in Kinshasa, (index tests). The reference laboratory will be blinded to the results of the&#xD;
      reference standard. For evaluation of diagnostic performance of the index tests, the&#xD;
      reference standard will consist of classification of treatment outcome according to&#xD;
      international standards applied for the clinical trial. Receiver operator curves, sensitivity&#xD;
      and specificity of the different index tests for treatment outcome assessment will be&#xD;
      determined at each follow-up time point. If sufficiently accurate, trypanosomal spliced&#xD;
      leader RNA detection in blood would allow post-treatment follow-up without the need for&#xD;
      lumbar punctures. Improved treatment outcome assessment will not only facilitate follow-up by&#xD;
      avoiding the feared lumbar puncture but also speed up the development and implementation of&#xD;
      new drugs. In addition, it will also improve management of patients in routine. The proposed&#xD;
      research will impact on clinical decision and treatment outcomes, and contribute to&#xD;
      successful HAT elimination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The reference laboratory, generating the results for the index test, is masked for results obtained at the clinical trial site (determining the standard reference).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for relapse after human African trypanosomiasis treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Index tests: qualitative detection of SL-RNA in blood, qualitative detection of SL-RNA in cerebrospinal fluid, neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid.&#xD;
Reference standard: classification according to the WHO 2015 criteria as relapse or probable relapse within 18 months after treatment for human African trypanosomiasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for cure after human African trypanosomiasis treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Index tests: qualitative detection of SL-RNA in blood, qualitative detection of SL-RNA in cerebrospinal fluid, neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid.&#xD;
Reference standard: classification according to the WHO 2015 criteria as cure or probable cure 18 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity SL-RNA detection in blood for outcome assesment after treatment for human African trypanosomiasis</measure>
    <time_frame>post treatment day 11, month 6, month 12 and month 18</time_frame>
    <description>Index tests: qualitative detection of SL-RNA in blood post treatment day 11, month 6, month 12 and month 18.&#xD;
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity SL-RNA detection in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis</measure>
    <time_frame>post treatment day 11, month 6, month 12 and month 18</time_frame>
    <description>Index tests: qualitative detection of SL-RNA in cerebrospinal fluid at post treatment day 11, month 6, month 12 and month 18.&#xD;
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity by ROC analysis of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis</measure>
    <time_frame>post treatment day 11, month 6, month 12 and month 18</time_frame>
    <description>Index tests: quantitative detection of neopterin &amp; 5-hydroxytryptophan in cerebrospinal fluid at post treatment day 11, month 6, month 12 and month 18.&#xD;
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>African Trypanosomiasis</condition>
  <condition>African; Trypanosomiasis, West</condition>
  <condition>Sleeping Sickness; West African</condition>
  <condition>Trypanosoma Brucei Gambiense; Infection</condition>
  <arm_group>
    <arm_group_label>Human african trypanosomiasis patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RNA, neopterin and 5-hydroxytryptophan detection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RNA and neopterin detection</intervention_name>
    <description>Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.</description>
    <arm_group_label>Human african trypanosomiasis patient</arm_group_label>
    <other_name>Reverse transcriptase real-time PCR Trypanozoon SL-RNA</other_name>
    <other_name>Neopterin &amp; 5-hydroxytryptophan EIA, Mybiosource</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for participation in DNDi-OXA-02-HAT clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excluded for DNDi-OXA-02-HAT clinical trial; No informed consent for participation in&#xD;
             the DiTECT-HAT-WP4 study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veerle Lejon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Programme Nationale de Lutte contre la trypanosomiase humaine Africaine</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <link>
    <url>http://apps.who.int/iris/bitstream/10665/173583/1/9789241508834_eng.pdf?ua=1</url>
    <description>Human African trypanosomiasis: update of the methodological framework for clinical trials</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT01533961</url>
    <description>phase 1 study of drug now in phase 2/3</description>
  </link>
  <reference>
    <citation>González-Andrade P, Camara M, Ilboudo H, Bucheton B, Jamonneau V, Deborggraeve S. Diagnosis of trypanosomatid infections: targeting the spliced leader RNA. J Mol Diagn. 2014 Jul;16(4):400-4. doi: 10.1016/j.jmoldx.2014.02.006. Epub 2014 May 9.</citation>
    <PMID>24814957</PMID>
  </reference>
  <reference>
    <citation>Ilboudo H, Camara O, Ravel S, Bucheton B, Lejon V, Camara M, Kaboré J, Jamonneau V, Deborggraeve S. Trypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA. J Infect Dis. 2015 Dec 15;212(12):1996-8. doi: 10.1093/infdis/jiv337. Epub 2015 Jun 16.</citation>
    <PMID>26080371</PMID>
  </reference>
  <reference>
    <citation>Tiberti N, Lejon V, Hainard A, Courtioux B, Robin X, Turck N, Kristensson K, Matovu E, Enyaru JC, Mumba Ngoyi D, Krishna S, Bisser S, Ndung'u JM, Büscher P, Sanchez JC. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2013;7(2):e2088. doi: 10.1371/journal.pntd.0002088. Epub 2013 Feb 28.</citation>
    <PMID>23469311</PMID>
  </reference>
  <reference>
    <citation>Vincent IM, Daly R, Courtioux B, Cattanach AM, Biéler S, Ndung'u JM, Bisser S, Barrett MP. Metabolomics Identifies Multiple Candidate Biomarkers to Diagnose and Stage Human African Trypanosomiasis. PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005140. doi: 10.1371/journal.pntd.0005140. eCollection 2016 Dec.</citation>
    <PMID>27941966</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diagnosis</keyword>
  <keyword>sensitivity</keyword>
  <keyword>specificity</keyword>
  <keyword>therapeutic outcome</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Trypanosomiasis, African</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>5-Hydroxytryptophan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

